Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › ASC30

ASC30

GLP-1 (small molecule) · oral / s.c. · Ascletis

Data cut 12 November 2026 · page built 16 November 2026 · 0 trial arms · 0 trials with results · 2 registered trials · see on the pipeline board

Summary

Also known as
Ascletis (oral small molecule and injectable)
Mechanism
GLP-1 (small molecule)
Route
oral / s.c.
Company
Ascletis
Highest development stage
phase 3
Status (as of data cut)
Oral phase 2 (13 weeks: placebo-adjusted −7.7 %); global phase 3 AURORA started (Aug 2026) verify
Next milestone
Phase 3

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity2 phase 3 ongoingOral phase 2 positive (13 weeks); phase 3 AURORA started Aug 2026
T2D2 phase 3 ongoingU.S. phase 2 topline (company release, October 2026): HbA1c 1.6–1.7 points and weight 3.8–4.4 % below placebo at 12–13 weeks; phase 3 registered on ClinicalTrials.govAscletis release, 28 Oct 2026
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

No trial arms with extracted efficacy or tolerability data yet.

Registered trials (2)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
AURORA-2
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
ObesityPhase 3recruiting2026-08 → 2028-071560recruitingNCT07743450
AURORA-1
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
ObesityPhase 3recruiting2026-08 → 2028-073003recruitingNCT07743463

Primary sources

No source recorded.

How to cite this page

Medical Adviser's Group. Incretin Atlas: ASC30. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/asc30/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.